TCRA Share Sales Programs

The TCRA funding plan rests on three assumptions.

The first assumption is that BIG4 will decide to adopt DLA and collect up to **$1 trillion** of royalty cash flow for TCRA.
The second assumption is that BIG4 will announce their plans for deploying DLA worldwide.

The third assumption: is that post-announcements TCRA's company value will be **$300 billion**.

Three TCRA share sales programs

First Series
Post-announcements, each 4 share block promised to early donors to WIRhE will return 100**x**, i.e. **$1 million** cash in Third Series secondary market sales of TCRA share by big players. Many friends, family and business people investors come to mind to whom WIRhE and TCI can offer the privilege to risk an early **100x** bet on TCRA shares.

Second Series
Post-announcements, in a separate TCRA share sale program a VC fund(s) will sell **1%** of TCRA shares owned by WIRhE to billionaire RhClub members - see RhClub Investors. This **1%** will return **$3 billion** to RhClub investors, when sold at post-announcements time along with the planned Third Series

Third Series
Post-announcements, TCRA company value will skyrocket to **~$300 billion** overnight straight after the Big 4 announcements make investors confident of the huge royalty cash flow. Our top PE firm will have established a secondary private asset fund(s) with limited partners committed to invest **$30 billion** in TCRA shares. The Big 4 will sell shares to LPs on this secondary market to fully fund DLA introduction. WIRhE will join the Big 4 sales to sell TCRA shares to realize a **$10 billion** endowment for WIRhE. Early investors The PC firm, the VC firm, Rh club members and TCI will also join the Big 4 sales post the DLA announcements.

The Pitch
TCRA has identified an enormous existing revenue stream of **$9 trillion** that can generate the payment of royalties of **$1 trillion** to TCRA over the next 20 years.

In a 'flash of luck' TCRA owns the perfect IP for the next generation of automated analyzers. Luckily an oligopoly of four major companies, *Siemens, Roche, Abbott, and*

Danaher, control the global clinical lab automation market and it's well within their power to use TCRA intellectual property in their next line of equipment and impose **$1 trillion** royalties on global clinical labs over 20 years. Owning **28%** of TCRA they will accrue them enormous new net profits that will reward their stock prices.

This revenue stream identified by TCRA will be earned by the huge **$240 billion** global clinical lab industry. These are the most assured revenues of any industry because **70%** of actionable medical care decisions are now based on clinical lab test results, which are absolutely fundamental in healthcare today. The **$1 trillion** royalties paid by clinical labs to TCRA shareholders will be earned on a US and International patent portfolio that TCRA owns covering new advanced dark clinical lab automation technology that the BIG 4 will install in their client clinical labs worldwide.

Applying royalties to clinical test data revenue is feasible today for the first time. Though royalties on intellectual property are normal in many industries, a royalty model paid by clinical labs, not by equipment manufacturers, has never been used before. Global clinical labs will pay royalties for using TCRA'S new patented Dark Lab Automation technology. DLA will make clinical labs much more efficient, with **80%** savings in inlab labor costs. The patents that TCRA happens to own will create an extraordinary return for all TCRA shareholders.

Issues
How will the 12,000 TCRA shares be donated to WIRhE?
How will custody of TCRA shares be managed for investors
How will we divide First Series sales between WIRhE and TCI
Should we have a time cutoff for First Series sales?
Complete subscriptions before any sale?
What are the SEC rules that apply to our First Series sales?
How will the later 90% of TCRA shares be transferred to WIRhE, UNICEF, Big 4, PE firm?
Should we have a lock-up period of say one month after the 100th block sale to prevent traders raising the price?
Can early investors trade shares to raise the price after the First Series sales?
Do we need a 401K to protect the early investors taxwise?
What would affect the 401k price?
?
?